Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Advicenne S.A. is a pharmaceutical company specializing in the development of innovative treatments for rare kidney diseases. With a focus on pediatric nephrology, Advicenne is dedicated to addressing unmet medical needs through its therapeutic products. The company's flagship product, often developed to respond to specific metabolic disorders, highlights Advicenne's commitment to niche areas within the medical field that require specialized care. It significantly impacts the healthcare industry by providing solutions that improve the quality of life for patients with limited treatment options. Headquartered in Nîmes, France, Advicenne is pivotal in advancing medical research and development for orphan diseases, enhancing its significance in the pharmaceutical market. Its innovative approach and targeted therapies make it a key player in the rare disease sector, underscoring the company's role in delivering effective and reliable healthcare solutions.
The business is unprofitable at the operating level (-139.13% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 20.8% YoY with margins expanding 43.0pp.
Negative free cash flow of -€4M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
€6M
▲ +20.8% YoY
Net Income (TTM)
-€10M
▼ -47.5% YoY
Op. Margin
-139.13%
▲ +43.0pp YoY
ROIC
-35.50%
▲ +2.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€4M
▼ -381.7% YoY
Op. Cash Flow (TTM)
-€4M
▼ -389.1% YoY
Net Debt
€18M
Cash & Equiv.
€1M
3Y CAGR: +17.4%
Continue Research